FMP

FMP

Enter

SYRS - Syros Pharmaceutical...

Financial Summary of Syros Pharmaceuticals, Inc.(SYRS), Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments f

photo-url-https://financialmodelingprep.com/image-stock/SYRS.png

Syros Pharmaceuticals, Inc.

SYRS

NASDAQ

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

5.76 USD

-0.16 (-2.78%)

About

ceo

Mr. Conley Chee

sector

Healthcare

industry

Biotechnology

website

https://www.syros.com

exchange

NASDAQ

Description

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced sol...

CIK

0001556263

ISIN

US87184Q2066

CUSIP

87184Q107

Address

35 CambridgePark Drive

Phone

617 744 1340

Country

US

Employee

117

IPO Date

Jun 30, 2016

Summary

CIK

0001556263

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

87184Q107

ISIN

US87184Q2066

Country

US

Price

5.76

Beta

1.79

Volume Avg.

222.26k

Market Cap

152.37M

Shares

-

52-Week

2.09-8.17

DCF

6.07

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

6.78

P/B

-

Website

https://www.syros.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest SYRS News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep